Next Article in Journal
OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity
Next Article in Special Issue
From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent
Previous Article in Journal
Emerging Fusarium Mycotoxins Fusaproliferin, Beauvericin, Enniatins, and Moniliformin in Serbian Maize
Previous Article in Special Issue
From Snake Venom’s Disintegrins and C-Type Lectins to Anti-Platelet Drugs
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle

Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson’s Disease

1
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea
2
Inist ST Co. Ltd., 159 Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do 13202, Korea
*
Author to whom correspondence should be addressed.
Toxins 2019, 11(6), 358; https://doi.org/10.3390/toxins11060358
Received: 31 May 2019 / Revised: 13 June 2019 / Accepted: 15 June 2019 / Published: 19 June 2019
(This article belongs to the Special Issue From Toxins to Drugs)
  |  
PDF [1746 KB, uploaded 19 June 2019]
  |     |  

Abstract

Bee venom contains a number of pharmacologically active components, including enzymes and polypeptides such as phospholipase A2 (PLA2) and melittin, which have been shown to exhibit therapeutic benefits, mainly via attenuation of inflammation, neurotoxicity, and nociception. The individual components of bee venom may manifest distinct biological actions and therapeutic potential. In this study, the potential mechanisms of action of PLA2 and melittin, among different compounds purified from honey bee venom, were evaluated against Parkinson’s disease (PD). Notably, bee venom PLA2 (bvPLA2), but not melittin, exhibited neuroprotective activity against PD in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP-induced behavioral deficits were also abolished after bvPLA2 treatment, depending on the PLA2 content. Further, bvPLA2 administration activated regulatory T cells (Tregs) while inhibiting inflammatory T helper (Th) 1 and Th17 cells in the MPTP mouse model of PD. These results indicate that bvPLA2, but not melittin, protected against MPTP and alleviated inflammation in PD. Thus, bvPLA2 is a promising and effective therapeutic agent in Parkinson’s disease. View Full-Text
Keywords: bee venom; phospholipase A2; melittin; Parkinson’s disease; neuroprotection; inflammation; regulatory T cells bee venom; phospholipase A2; melittin; Parkinson’s disease; neuroprotection; inflammation; regulatory T cells
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kim, K.H.; Kim, M.; Lee, J.; Jeon, H.N.; Kim, S.H.; Bae, H. Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson’s Disease. Toxins 2019, 11, 358.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top